Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 20/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 14/20 | 1.00 |
| ▸ | FYN | P06241 | 1/20 | 0.76 |
| ▸ | CSF1R | P07333 | 1/20 | 0.76 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.76 |
| ▸ | KIT | P10721 | 1/20 | 0.76 |
| ▸ | SRC | P12931 | 1/20 | 0.76 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.76 |
| ▸ | FLT1 | P17948 | 1/20 | 0.76 |
| ▸ | FLT4 | P35916 | 1/20 | 0.76 |
| ▸ | FLT3 | P36888 | 1/20 | 0.76 |
| ▸ | TEK | Q02763 | 1/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5929568 | 0.89 | KDR (1.00) | KDRKCNH2FYNCSF1RPDGFRB | |
| SCHEMBL5929620 | 0.88 | KDR (0.82) | KDRKCNH2FYNCSF1RPDGFRB | |
| SCHEMBL4814667 | 0.88 | KDR (1.00) | KDRKCNH2FYNCSF1RPDGFRB | |
| SCHEMBL4813916 | 0.86 | KDR (1.00) | KDRKCNH2FYNCSF1RPDGFRB | |
| SCHEMBL4814537 | 0.85 | KDR (0.89) | KDRKCNH2FYNCSF1RPDGFRB | |
| SCHEMBL4820603 | 0.85 | KDR (0.77) | KDRKCNH2FYNCSF1RPDGFRB | |
| SCHEMBL4816560 | 0.84 | KDR (0.75) | KDRKCNH2FYNCSF1RPDGFRB | |
| SCHEMBL5929537 | 0.84 | KDR (1.00) | KDRKCNH2FYNCSF1RPDGFRB | |
| SCHEMBL4812557 | 0.83 | KDR (0.74) | KDRKCNH2FYNCSF1RPDGFRB | |
| SCHEMBL4817791 | 0.83 | KDR (0.73) | KDRKCNH2FYNCSF1RPDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1740579-B1 | TRICYCLIC PYRAZOLE KINASE INHIBITORS | ABBVIE INC (US) | 2015-08-19 | — | — | EP | disclosed |
| US-7468371-B2 | Tricyclic pyrazole kinase inhibitors | ABBOTT LABORATORIES INC. (US) | 2008-12-23 | — | — | US | disclosed |
| US-20060014816-A1 | Tricyclic pyrazole kinase inhibitors | ABBVIE INC. | 2006-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014816-A1 | Tricyclic pyrazole kinase inhibitors | PRKDC, PRKACA, PIK3C3 | KDR 666/4885KCNH2 2628/4885FYN 202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.